A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Response rates to tipifarib defined as the proportion of patients achieving a complete response (CCR) or partial response (PR)
研究概览
简要总结
This phase II trial is studying how well tipifarnib works in treating patients with anemia or neutropenia and large granular lymphocyte leukemia. Tipifarnib may stop the growth of leukemia by blocking blood flow to the cancer cells and by blocking some of the enzymes needed for cancer cell growth.
详细描述
PRIMARY OBJECTIVES:
I. Estimate the complete response rate, partial response rate, and overall response rate in patients with natural killer (NK)- or T-cell-large granular lymphocyte (LGL) leukemia who present with neutropenia or anemia treated with tipifarnib.
SECONDARY OBJECTIVES:
I. Determine the toxicity of tipifarnib in these patients. II. Determine the mechanism of treatment responses in these patients through correlative laboratory studies.
OUTLINE: Patients are stratified by disease type (natural killer-large granular lymphocyte [LGL] leukemia vs T-cell-LGL leukemia).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of T-cell-large granular lymphocyte (LGL) leukemia or natural killer (NK)-LGL leukemia associated with ≥ 1 of the following clinical manifestations:
- •Severe neutropenia (i.e., < 500/mm³)
- •Neutropenia associated with recurrent infections, meeting 1 of the following criteria: one severe infection requiring hospitalization or at least 2 infections requiring antibiotic therapy
- •Symptomatic anemia with significant fatigue with a score of greater than 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale; dyspnea on exertion, but able to walk one flight of stairs without stopping (less than grade 1 respiratory symptoms); cardiac symptoms including worsening of angina or new onset of chest pain
- •Transfusion-dependent anemia
- •Willing to discontinue use of MTX, Cy, or cyclosporine for 1 month prior to study entry
- •T-cell-LGL leukemia must meet all of the following criteria: CD3+ and CD57+ cells > 300/mm³ or CD8+ cells > 650/mm³ by phenotypic studies of peripheral blood, evidence for clonal T-cell receptor gene rearrangement based on positive flow cytometric analysis, T-cell receptor (TCR)-γ chain polymerase chain reaction (PCR), TCR-Vβ PCR, or by Southern blot analysis
- •NK-LGL leukemia must have CD56+ or CD16+ NK cells > 750/mm³ by phenotypic studies of peripheral blood
- •Life expectancy > 2 years
- •ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
- •Fertile patients must use effective contraception prior to and during study
- •Negative pregnancy test
- •Normal kidney and liver function, as determined by the following laboratory results: total bilirubin less than or equal to 2.0 mg/dl; AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times the upper limit of normal; and creatinine less than or equal to 2.0 mg/dl
排除标准
- •Not pregnant or nursing
- •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to tipifarnib
- •No allergies to imidazoles (e.g., clotrimazole, ketoconazole, miconazole, econazole, fenticonazole, isoconazole, sulconazole, tioconazole, or terconazole)
- •No uncontrolled concurrent illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness or social situations that would limit study compliance
- •No other serious medical illness that would limit survival to < 2 years
- •No other malignancy within the past 5 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix
- •Psychiatric illness that may interfere with study participation
- •No other anticancer agents or therapies
- •No concurrent antiretroviral therapy for HIV-positive patients
- •No other concurrent investigational agents
- •No prior tipifarnib or other inhibitors of MAPK signaling intermediates
研究组 & 干预措施
Arm I
Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.
Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years.
干预措施: tipifarnib (Drug)
Arm I
Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.
Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Response rates to tipifarib defined as the proportion of patients achieving a complete response (CCR) or partial response (PR)
时间窗: Up to 5 years
次要结局
- Changes in Ras/ERK and NK receptor expression(Baseline to 5 years)